ACADIA PHARMS INC — Patent Portfolio
1 drug with active patents · 32 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict The Acadia Pharmaceuticals portfolio is moderately strong, with a significant cliff year in 2032 and no revenue at risk in the next 5 years.
Portfolio overview The Acadia Pharmaceuticals portfolio consists of a total of 2 drugs, with 1 of them having patents. The company has a total of 32 US patents, all of which are active. The average vulnerability score of the patents is 62, indicating a moderate level of vulnerability. Out of the total patents, 4 are considered ironclad, while 12 are vulnerable. The company does not have any biologics in its portfolio.
Cliff calendar The company faces a significant cliff year in 2032, with 1 drug losing exclusivity. This includes Daybue, which will lose exclusivity on January 27, 2032. Additionally, 1 drug will lose exclusivity in 2032.
Most exposed drugs The top drug facing near-term loss of exclusivity is Daybue, with an earliest active patent expiry date of January 27, 2032, an average vulnerability score of 62, and annual revenue of $300 million USD. This drug has a total of 32 patents.
Biologic exclusivity The company does not have any biologics in its portfolio, and therefore does not have any biologic exclusivity.
Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity of Daybue in 2032 may require the company to consider lifecycle moves such as subQ switches, label extensions, or combination filings to maintain revenue.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Daybue (TROFINETIDE)
Cliff 2032 · 6y-
US9212204
Vuln 81
2032-01-27
This patent protects methods for treating Autism Spectrum Disorders, including Rett Syndrome, using glycyl-2-methylprolyl-glutamic acid and its analogs.
-
US9212204
Vuln 81
2032-01-27
This patent protects methods for treating Autism Spectrum Disorders, including Rett Syndrome, using glycyl-2-methylprolyl-glutamic acid and its analogs.
-
US9212204
Vuln 81
2032-01-27
This patent protects methods for treating Autism Spectrum Disorders, including Rett Syndrome, using glycyl-2-methylprolyl-glutamic acid and its analogs.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Other 16 patents
- Method of Use 12 patents
- Composition of Matter 4 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track ACADIA PHARMS INC's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export